108 related articles for article (PubMed ID: 17660346)
1. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma.
Altundag K; Dede DS; Purnak T
J Clin Pathol; 2007 Aug; 60(8):958. PubMed ID: 17660346
[No Abstract] [Full Text] [Related]
2. Albumin-bound paclitaxel, ABI-007 may show better efficacy than paclitaxel in basal-like breast cancers: association between caveolin-1 expression and ABI-007.
Altundag K; Bulut N; Dizdar O; Harputluoglu H
Breast Cancer Res Treat; 2006 Dec; 100(3):329-30. PubMed ID: 16897435
[No Abstract] [Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer.
Harries M; Ellis P; Harper P
J Clin Oncol; 2005 Nov; 23(31):7768-71. PubMed ID: 16204007
[No Abstract] [Full Text] [Related]
4. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
[TBL] [Abstract][Full Text] [Related]
5. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy.
Henderson IC; Bhatia V
Expert Rev Anticancer Ther; 2007 Jul; 7(7):919-43. PubMed ID: 17627452
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
Ciruelos E; Jackisch C
Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
[TBL] [Abstract][Full Text] [Related]
7. Albumin-bound paclitaxel (Abraxane) for advanced breast cancer.
Med Lett Drugs Ther; 2005 May; 47(1208):39-40. PubMed ID: 15880087
[TBL] [Abstract][Full Text] [Related]
8. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma.
Perez-Ruiz E; Ribelles N; Sanchez-Muñoz A; Roman A; Marquez A
Acta Oncol; 2009; 48(7):1078-9. PubMed ID: 19235566
[No Abstract] [Full Text] [Related]
9. Treatment of advanced breast cancer: How much chemotherapy is enough?
DiPaola RS; Kaufman A; Mikhail MM
Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
[No Abstract] [Full Text] [Related]
10. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
Choi BS; Robins HI
Cancer Chemother Pharmacol; 2008 Feb; 61(2):345-6. PubMed ID: 18026678
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-induced cardiotoxicity. An ultrastructural study.
Shek TW; Luk IS; Ma L; Cheung KL
Arch Pathol Lab Med; 1996 Jan; 120(1):89-91. PubMed ID: 8554453
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-induced acral erythema.
Richards KN; Ivan D; Rashid RM; Chon SY
Arch Dermatol; 2012 Nov; 148(11):1333-4. PubMed ID: 23165853
[No Abstract] [Full Text] [Related]
13. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency.
Villano JL; Mehta D; Radhakrishnan L
Invest New Drugs; 2006 Sep; 24(5):455-6. PubMed ID: 16505953
[No Abstract] [Full Text] [Related]
14. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer.
Moreno-Aspitia A; Perez EA
Future Oncol; 2005 Dec; 1(6):755-62. PubMed ID: 16556053
[TBL] [Abstract][Full Text] [Related]
15. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
16. Peripheral neuropathy in a woman with breast cancer.
Cianfrocca M; Flatters SJ; Bennett GJ; McNicol E; Relias V; Carr D; Gillis TA
J Pain; 2006 Jan; 7(1):2-10. PubMed ID: 16414547
[No Abstract] [Full Text] [Related]
17. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
19. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
Klaassen U; Seeber S
Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
[No Abstract] [Full Text] [Related]
20. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
Petrelli F; Borgonovo K; Barni S
Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
